Winchester, MA, United States of America

Feng Li

USPTO Granted Patents = 14 (Patent Applications = 12)

CIPO Patents = 4 (Patent Applications = 3)

EPO Patents = 5 (Patent Applications = 10)

Average Co-Inventor Count = 5.8

ph-index = 5

Forward Citations = 55(Granted Patents)

Location History:

Dresher, PA (US) (2017 - 2020)
Cambridge, MA (US) (2021 - 2023)
Winchester, MA (US) (2014 - 2024)

Company Filing History:

11 out of 69

Ariad Pharmaceuticals, Inc.

patents

2 out of 2,405

Merck Sharp + Dohme Corp.

patents

1 out of 1,177

Takeda Pharmaceutical Company Limited

patents

Years Active: 2014-2024

where 'Filed Patents' based on already Granted Patents

14 patents (USPTO):Sort by Forward Citations

Abstract keywords

1. 11958850 - Heteroaryl compounds for kinase inhibition (2024-04-16),

2. 11753404 - Aminothiazole compounds as c-Kit inhibitors (2023-09-12),

3. 11117883 - Benzimidazole compounds as c-Kit inhibitors (2021-09-14),

4. 11001580 - Aminothiazole compounds as c-Kit inhibitors (2021-05-11),

5. 10772888 - Solid pharmaceutical compositions containing an integrase inhibitor (2020-09-15),

6. 10227342 - Heteroaryl compounds for kinase inhibition (2019-03-12),

7. 9834521 - Choline kinase inhibitors (2017-12-05),

8. 9796712 - Heteroaryl compounds for kinase inhibition (2017-10-24),

9. 9649311 - Solid pharmaceutical compositions containing an integrase inhibitor (2017-05-16),

10. 9573934 - Methods and compositions for the synthesis of multimerizing agents (2017-02-21),

11. 9273077 - Phosphorus derivatives as kinase inhibitors (2016-03-01),

12. 9024028 - Methods and compositions for the synthesis of multimerizing agents (2015-05-05),

13. 9012462 - Phosphorous derivatives as kinase inhibitors (2015-04-21),

14. 8912330 - Azaindole derivatives as kinase inhibitors (2014-12-16),

Title: The Innovative Contributions of Feng Li

Introduction

Feng Li is a prominent inventor based in Winchester, MA (US), known for his significant contributions to the field of pharmaceutical sciences. With a total of 14 patents to his name, he has made remarkable advancements in the development of compounds that target specific kinase activities.

Latest Patents

Feng Li's latest patents include groundbreaking work on heteroaryl compounds for kinase inhibition. These compounds and pharmaceutical compositions are designed to modulate kinase activity, particularly focusing on mutant EGFR and mutant HER2 kinase activity. Additionally, he has developed aminothiazole compounds as c-Kit inhibitors, which are useful in treating cancers and other diseases mediated by serine-threonine kinases.

Career Highlights

Throughout his career, Feng Li has worked with notable companies such as Ariad Pharmaceuticals, Inc. and Merck Sharp & Dohme Corporation. His work in these organizations has contributed to the advancement of cancer therapies and other medical treatments.

Collaborations

Feng Li has collaborated with esteemed colleagues, including William C. Shakespeare and Xiaotian Zhu, further enhancing the impact of his research and innovations.

Conclusion

Feng Li's contributions to the field of pharmaceutical sciences through his innovative patents and collaborations have made a significant impact on cancer treatment and kinase inhibition. His work continues to inspire advancements in medical research and development.

This text is generated by artificial intelligence and may not be accurate.